v3.26.1
Merger with AlloVir - Additional Information (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 18, 2025
USD ($)
$ / shares
shares
Jan. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2026
USD ($)
$ / shares
Mar. 31, 2025
USD ($)
Jan. 31, 2024
$ / shares
shares
Business Acquisition [Line Items]          
Exercise price per share, cancelled | $ / shares     $ 3.71    
Stock-based compensation expense     $ 580 $ 374  
General and Administrative          
Business Acquisition [Line Items]          
Stock-based compensation expense     $ 412 $ 280  
AlloVir          
Business Acquisition [Line Items]          
Merger agreement date Mar. 18, 2025        
Interest rate   8.00%      
Equity own percentage 25.53%        
Cash and cash equivalents $ 102,100        
Prepaid expenses and other current assets 1,700        
Accounts payable and accrued expenses 2,600        
Director's and officer's insurance recognized 1,500        
Transaction costs $ 5,400        
AlloVir | Common Stock          
Business Acquisition [Line Items]          
Common stock shares issued | shares 13,634,744        
AlloVir | Stock Options | General and Administrative          
Business Acquisition [Line Items]          
Stock-based compensation expense $ 100        
AlloVir | Restricted Stock Units | General and Administrative          
Business Acquisition [Line Items]          
Stock-based compensation expense $ 100        
Kalaris Therapeutics, Inc.          
Business Acquisition [Line Items]          
Equity own percentage 74.47%        
Series B-2 Redeemable Convertible Preferred Stock          
Business Acquisition [Line Items]          
Redeemable convertible preferred stock, shares issued | shares         1,280,000
Price per share | $ / shares         $ 1.25
2024 Convertible Promissory Note | Kalaris Therapeutics, Inc.          
Business Acquisition [Line Items]          
Common stock price per share | $ / shares   $ 6.2      
Debt instrument, issued, principal amount   $ 3,750      
2024 Convertible Promissory Note | Redeemable Convertible Preferred Stock | AlloVir          
Business Acquisition [Line Items]          
Redeemable convertible preferred stock, shares issued | shares 0.2016        
Conversion ratios 4.9603        
2024 Convertible Promissory Note | Series B-2 Redeemable Convertible Preferred Stock | Kalaris Therapeutics, Inc.          
Business Acquisition [Line Items]          
Redeemable convertible preferred stock, shares issued | shares   794,499      
Price per share | $ / shares   $ 4.7851      
Conversion ratios   1      
Maximum | AlloVir          
Business Acquisition [Line Items]          
Exercise price per share unvested and unexercised | $ / shares $ 92        
Maximum | 2024 Convertible Promissory Note | AlloVir          
Business Acquisition [Line Items]          
Debt instrument, issued, principal amount   $ 7,500      
Minimum | AlloVir          
Business Acquisition [Line Items]          
Exercise price per share, cancelled | $ / shares $ 92